Register for the 2022 Policy Outlook Webinar Today; Ask Congress to Support Cures 2.0; AMCP Releases State Model Legislation; CMS Actions on Alzheimer’s Drugs and 2023 Part D Rule; Request for Medicare Payment Advisory Commission(MedPAC) Nominations.
AMCP Publishes New Pay-for-Performance Principles; AMCP Joins Public Health Leaders in Defense of OSHA’s COVID-19 Vaccine Rule; AMCP Supports Dr. Robert Califf’s Nomination for FDA Commissioner; ICYMI: AMCP Quarterly Legislative and Regulatory Briefing Now Available; Reps. DeGette and Upton Release the Cures 2.0 Act; AMCP Seeking New Regulatory Affairs Director.
AMCP Submits Comments on PDUFA; AMCP Joins Influenza Antiviral Sign-on Letter; AMCP Joins COVID-19 Antiviral Recommendations Sign-on Letter; President Biden Signs Infrastructure Investment and Jobs Act; President Biden To Nominate Dr. Robert Califf for FDA Commissioner.
AMCP Celebrates Grassroots Advocates at Nexus 2021; Congress Passes Continuing Resolution to Avoid Government Shutdown; Raises Debt Ceiling to Avert Default; FDA and CDC Approve Pfizer Booster; CMS Releases 2022 Premiums and Cost-Sharing Information for Medicare Advantage & Part D Plans; CMS Releases MA, Part D Star Ratings for 2022; MACPAC Report on Medicaid Churn.
Join us for a Grassroots Reception at Nexus 2021; Expanding Access to COVID-19 Therapeutics –HHS PREP Act Declaration: Ninth Amendment; HHS Comprehensive Plan for Addressing High Drug Prices; AMCP Virtual Legislative Days 2021; ICYMI: Respond to AMCP Policy Action Items Survey; AMCP Urges Congress to Implement Continuous Eligibility for Children in Medicaid and CHIP.
AMCP Urges HHS to Extend Medicare Part D Enhanced MTM Mode; Biden Administration Withdraws the Most Favored Nations Model; AMCP Supports FDA Approval of Biosimilar Insulin; President Biden Calls on Congress to Reduce Drug Prices.
